CHC Healthcare Group Future Growth

Future criteria checks 4/6

CHC Healthcare Group is forecast to grow earnings and revenue by 68.3% and 15.5% per annum respectively while EPS is expected to grow by 68.2% per annum.

Key information

68.3%

Earnings growth rate

68.2%

EPS growth rate

Healthcare earnings growth	19.1%
Revenue growth rate	15.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	23 Oct 2024

Recent future growth updates

Recent updates

CHC Healthcare Group (TWSE:4164) Will Pay A Larger Dividend Than Last Year At NT$2

Jun 29

CHC Healthcare Group's (TWSE:4164) Dividend Will Be Increased To NT$2.01

Jun 15

If You Had Bought CHC Healthcare Group's (TPE:4164) Shares Five Years Ago You Would Be Down 36%

Mar 08

CHC Healthcare Group's (TPE:4164) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Feb 07

CHC Healthcare Group (TPE:4164) Share Prices Have Dropped 32% In The Last Five Years

Dec 07

Are CHC Healthcare Group's (TPE:4164) Statutory Earnings A Good Guide To Its Underlying Profitability?

Nov 22

Earnings and Revenue Growth Forecasts

TWSE:4164 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	4,620	513	N/A	N/A	1
12/31/2024	3,575	124	561	1,061	1
9/30/2024	4,032	324	22	462	N/A
6/30/2024	3,807	274	416	863	N/A
3/31/2024	3,734	342	580	1,232	N/A
12/31/2023	3,877	419	387	963	N/A
9/30/2023	3,283	302	-120	480	N/A
6/30/2023	3,362	360	-148	534	N/A
3/31/2023	3,168	376	-331	321	N/A
12/31/2022	2,974	357	-26	657	N/A
9/30/2022	2,992	409	197	873	N/A
6/30/2022	2,654	375	62	676	N/A
3/31/2022	2,405	337	124	717	N/A
12/31/2021	2,440	382	179	693	N/A
9/30/2021	2,098	294	43	795	N/A
6/30/2021	2,451	383	177	913	N/A
3/31/2021	2,641	400	280	898	N/A
12/31/2020	2,555	366	195	916	N/A
9/30/2020	2,630	396	747	1,245	N/A
6/30/2020	2,741	393	836	1,245	N/A
3/31/2020	2,875	407	1,015	1,401	N/A
12/31/2019	2,950	395	871	1,215	N/A
9/30/2019	3,003	402	121	444	N/A
6/30/2019	2,791	347	39	357	N/A
3/31/2019	2,733	366	-296	147	N/A
12/31/2018	2,507	323	-33	338	N/A
9/30/2018	2,463	37	33	391	N/A
6/30/2018	2,193	-39	N/A	454	N/A
3/31/2018	1,948	-142	N/A	420	N/A
12/31/2017	2,117	-87	N/A	294	N/A
9/30/2017	2,307	240	N/A	512	N/A
6/30/2017	2,242	232	N/A	445	N/A
3/31/2017	2,418	227	N/A	735	N/A
12/31/2016	2,205	159	N/A	845	N/A
9/30/2016	2,165	133	N/A	628	N/A
6/30/2016	2,366	185	N/A	786	N/A
3/31/2016	2,450	271	N/A	782	N/A
12/31/2015	2,395	227	N/A	576	N/A
9/30/2015	2,363	236	N/A	732	N/A
6/30/2015	2,176	205	N/A	612	N/A
3/31/2015	1,974	189	N/A	436	N/A
12/31/2014	2,091	266	N/A	634	N/A
9/30/2014	2,000	242	N/A	738	N/A
6/30/2014	2,240	326	N/A	596	N/A
3/31/2014	2,117	328	N/A	673	N/A
12/31/2013	2,063	297	N/A	867	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4164's forecast earnings growth (68.3% per year) is above the savings rate (1.1%).

Earnings vs Market: 4164's earnings (68.3% per year) are forecast to grow faster than the TW market (19.2% per year).

High Growth Earnings: 4164's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4164's revenue (15.5% per year) is forecast to grow faster than the TW market (12.1% per year).

High Growth Revenue: 4164's revenue (15.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4164's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 20:46
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CHC Healthcare Group is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhennan Lee	Jih Sun Securities Investment Consulting Co., Ltd.
Joseph Quinn	Macquarie Research
Xiaowei Huang	Masterlink Securities Corp.

CHC Healthcare Group Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 60%, revenue upgraded

Consensus revenue estimates fall by 15%

Price target decreased by 8.6% to NT$69.00

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 17%

Price target decreased to NT$47.00

Recent updates

New major risk - Financial data availability

Now 21% undervalued after recent price drop

Third quarter 2024 earnings: EPS exceeds analyst expectations

CHC Healthcare Group to Report Q3, 2024 Results on Nov 06, 2024

Consensus EPS estimates fall by 60%, revenue upgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

CHC Healthcare Group to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$2.00 per share

CHC Healthcare Group (TWSE:4164) Will Pay A Larger Dividend Than Last Year At NT$2

CHC Healthcare Group's (TWSE:4164) Dividend Will Be Increased To NT$2.01

Dividend increased to NT$2.01

CHC Healthcare Group Approves Cash Dividend, Payable on August 1, 2024

Consensus revenue estimates fall by 15%

Price target decreased by 8.6% to NT$69.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CHC Healthcare Group has filed a Follow-on Equity Offering in the amount of TWD 139.7 million.

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CHC Healthcare Group, Annual General Meeting, Jun 12, 2024

Consensus EPS estimates fall by 14%

New minor risk - Profit margin trend

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 17%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Upcoming dividend of NT$1.97 per share at 2.9% yield

Investor sentiment improves as stock rises 15%

CHC Healthcare Group Announces Sustainability Committee Changes

CHC Healthcare Group Announces Change of Audit Committee

CHC Healthcare Group announced a financing transaction

Now 25% undervalued

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Price target decreased to NT$47.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to NT$46.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$2.01 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.43 (vs NT$1.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.47 (vs NT$0.64 in 2Q 2020)

Director Yung-Shun Chuang has joined 7th company board

Upcoming dividend of NT$2.01 per share

First quarter 2021 earnings released: EPS NT$0.67 (vs NT$0.51 in 1Q 2020)

CHC Healthcare Group. Announces the Appointment of Pei-Lin Lee as CIO & CHRO of the Company, Effective March 19, 2021

CHC Healthcare Group, Annual General Meeting, Jun 16, 2021

Full year 2020 earnings released: EPS NT$2.53 (vs NT$2.83 in FY 2019)

If You Had Bought CHC Healthcare Group's (TPE:4164) Shares Five Years Ago You Would Be Down 36%

CHC Healthcare Group's (TPE:4164) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Should CHC Healthcare Group (TPE:4164) Be Part Of Your Dividend Portfolio?

New 90-day low: NT$36.80

Is CHC Healthcare Group (TPE:4164) Likely To Turn Things Around?

Is CHC Healthcare Group (TPE:4164) Using Too Much Debt?

CHC Healthcare Group (TPE:4164) Share Prices Have Dropped 32% In The Last Five Years

Are CHC Healthcare Group's (TPE:4164) Statutory Earnings A Good Guide To Its Underlying Profitability?

CHC Healthcare Group Announces Board Appointments

Third quarter 2020 earnings released: EPS NT$1.08

New 90-day low: NT$37.30

New 90-day low: NT$37.90

New 90-day low - NT$39.10

First half earnings released

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity